Ceritinib in Second and Further Lines of Therapy in Advanced ALK Mutant Adenocarcinoma

Journal of Thoracic Disease - Hong Kong
doi 10.21037/jtd.2016.05.53
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AME Publishing Company

Related search

Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Proactive Management Strategies for Potential Gastrointestinal Adverse Reactions With Ceritinib in Patients With Advanced ALK-positive Non-Small-Cell Lung Cancer

Cancer Management and Research
Oncology
2016English

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma

PLoS ONE
Multidisciplinary
2016English

Ceritinib Plus Nivolumab in Patients With Advanced ALK-rearranged Non-Small-Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2020English

Maximizing Response and Outcomes in Multimodality Therapy for Locally Advanced Esophageal Adenocarcinoma

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Successful Rechallenge With Ceritinib After Leukocytoclastic Vasculitis During Ceritinib Treatment for Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Protein

Oncotarget
Oncology
2018English

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy